| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $260,649 | 8 | 100 |
| Bjorkquist Jeanette M | PFO and PAO | 0 | $0 | 4 | $32,005 | $-32,005 |
| Gaggar Anuj | Chief Medical Officer | 0 | $0 | 1 | $50,864 | $-50,864 |
| White Nicole S | Chief Manufacturing Officer | 0 | $0 | 2 | $56,122 | $-56,122 |
| Okazaki Jason A | CEO and President | 0 | $0 | 1 | $121,658 | $-121,658 |
Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment. Assembly Biosciences has …
Over the last 12 months, insiders at Assembly Biosciences, Inc. have bought $0 and sold $260,649 worth of Assembly Biosciences, Inc. stock.
On average, over the past 5 years, insiders at Assembly Biosciences, Inc. have bought $10.79M and sold $116,796 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,295,920 shares for transaction amount of $2,296 was made by GILEAD SCIENCES, INC. (10 percent owner) on 2025‑08‑08.
| 2026-11-02 | Sale | Okazaki Jason A | CEO and President | 6,202 0.0331% | $19.62 | $121,658 | +1.55% | |
| 2026-11-02 | Sale | White Nicole S | Chief Manufacturing Officer | 2,593 0.0138% | $19.62 | $50,864 | +1.55% | |
| 2026-11-02 | Sale | Gaggar Anuj | Chief Medical Officer | 2,593 0.0138% | $19.62 | $50,864 | +1.55% | |
| 2026-11-02 | Sale | Bjorkquist Jeanette M | PFO and PAO | 727 0.0039% | $19.62 | $14,261 | +1.55% | |
| 2026-06-17 | Sale | Bjorkquist Jeanette M | PFO and PAO | 29 0.0002% | $23.25 | $674 | +7.56% | |
| 2026-03-30 | Sale | White Nicole S | Chief Manufacturing Officer | 197 0.0012% | $26.69 | $5,258 | +0.38% | |
| 2026-03-30 | Sale | Bjorkquist Jeanette M | PFO and PAO | 312 0.002% | $26.65 | $8,315 | +0.38% | |
| 2026-03-30 | Sale | Bjorkquist Jeanette M | PFO and PAO | 328 0.0021% | $26.69 | $8,755 | +0.38% | |
| 2025-08-08 | GILEAD SCIENCES, INC. | 10 percent owner | 2.3M 0.0012% | $0.00 | $2,296 | +15.71% | ||
| 2025-03-31 | Sale | McHutchison John G | director | 757 0.0104% | $9.85 | $7,455 | +168.41% | |
| 2025-03-31 | Sale | Okazaki Jason A | CEO and President | 355 0.0049% | $9.85 | $3,496 | +168.41% | |
| 2025-03-31 | Sale | White Nicole S | Chief Manufacturing Officer | 197 0.0027% | $9.85 | $1,940 | +168.41% | |
| 2025-03-31 | Sale | Bjorkquist Jeanette M | Principal Accounting Officer | 180 0.0025% | $9.85 | $1,773 | +168.41% | |
| 2024-12-30 | Houghton Michael | director | 3,202 0.0519% | $15.61 | $49,998 | +12.35% | ||
| 2024-12-19 | GILEAD SCIENCES, INC. | 10 percent owner | 940,499 20.3736% | $21.37 | $20.1M | +9.80% | ||
| 2024-11-25 | Schornstein Alexander | 10 percent owner | 7,976 0.126% | $14.91 | $118,890 | +13.37% | ||
| 2024-11-22 | Schornstein Alexander | 10 percent owner | 17,024 0.2729% | $14.87 | $253,104 | +11.04% | ||
| 2024-11-18 | Sale | White Nicole S | Chief Manufacturing Officer | 40 0.0006% | $16.29 | $652 | +2.75% | |
| 2024-10-08 | Schornstein Alexander | 10 percent owner | 10,000 0.1478% | $14.58 | $145,800 | +11.37% | ||
| 2024-10-03 | Sale | Okazaki Jason A | CEO and President | 197 0.003% | $14.81 | $2,918 | +9.02% |
| GILEAD SCIENCES, INC. | 10 percent owner | 4505391 22.128% | $89.75M | 3 | 0 | +7.5% |
| Schornstein Alexander | 10 percent owner | 728113 3.5761% | $14.5M | 9 | 0 | +36.18% |
| Small Derek A | CEO and President | 669291 3.2872% | $13.33M | 3 | 0 | <0.0001% |
| ELLISON RUSSELL H | Chief Executive Officer | 58000 0.2849% | $1.16M | 6 | 0 | +59.75% |
| BARRETT DAVID JONATHAN | Chief Financial Officer | 46980 0.2307% | $935,841.60 | 3 | 0 | +86.04% |
| Houghton Michael | director | 3202 0.0157% | $63,783.84 | 1 | 0 | +12.35% |
$3,887,391 | 114 | 13.01% | $433.37M | |
$31,123,523 | 108 | 6.46% | $387.86M | |
$24,384,691 | 42 | -30.27% | $396.82M | |
$2,481,409 | 33 | 201.68% | $455.48M | |
$8,866,498 | 28 | 33.64% | $474.26M |
| Increased Positions | 47 | +88.68% | 2M | +17.99% |
| Decreased Positions | 21 | -39.62% | 1M | -8.32% |
| New Positions | 24 | New | 1M | New |
| Sold Out Positions | 8 | Sold Out | 566,594 | Sold Out |
| Total Postitions | 79 | +49.06% | 14M | +9.66% |
| Gilead Sciences, Inc. | $152,034.00 | 28.16% | 4.51M | +2M | +103.91% | 2025-09-30 |
| Farallon Capital Management Llc | $41,425.00 | 7.67% | 1.23M | +1M | New | 2025-09-30 |
| Ra Capital Management, L.P. | $34,434.00 | 6.38% | 1.02M | +1M | New | 2025-09-30 |
| Commodore Capital Lp | $33,745.00 | 6.25% | 1M | +1M | New | 2025-09-30 |
| Janus Henderson Group Plc | $25,397.00 | 4.7% | 752,626 | +752,626 | New | 2025-09-30 |
| Vanguard Group Inc | $16,944.00 | 3.14% | 502,112 | +248,287 | +97.82% | 2025-09-30 |
| Frazier Life Sciences Management, L.P. | $15,396.00 | 2.85% | 456,249 | +456,249 | New | 2025-09-30 |
| Blackstone Inc. | $15,111.00 | 2.8% | 447,789 | +447,789 | New | 2025-09-30 |
| Point72 Asset Management, L.P. | $9,989.00 | 1.85% | 296,017 | +296,017 | New | 2025-09-30 |
| Parkman Healthcare Partners Llc | $8,469.00 | 1.57% | 250,981 | +250,981 | New | 2025-09-30 |